This design led to tumor accumulation and efficacy in lymphoma, multiple myeloma, and melanoma models comparable to untargeted and wild-type IFN-α immunocytokines, though with significantly less toxicity [141,142]. This evidence concerns the gene IFNA2 and neoplasm.